🇺🇸 FDA
Pipeline program

METFORMIN

P170901J

Phase 3 small_molecule active

Quick answer

METFORMIN for Type 2 Diabetes complete remission after bariatric surgery under antidiabetic drug is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Type 2 Diabetes complete remission after bariatric surgery under antidiabetic drug
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials